How Tianeptine Became A Valuable Tool In Neuroscience Studies

IMPORTANT DISCLAIMER: This article is for educational and informational purposes only. Tianeptine is sold strictly as a research chemical for laboratory use only. It is NOT intended for human consumption, animal consumption, or any clinical use. This material is intended solely for in vitro research, analytical reference standards, and forensic applications by qualified researchers in properly equipped laboratory facilities. It is not approved by the FDA for any medical use. Always consult applicable laws and regulations in your jurisdiction.

Tianeptine became a neuroscience research tool because laboratory findings kept overturning the accepted explanation of how it acts. It was discovered in the 1960s at the French Society of Medical Research. Since then, published studies have tied it to 3 mechanisms in turn: serotonin uptake in the late 1980s, glutamate signaling and stress-related structural plasticity from the 1990s, and mu-opioid receptor (MOR) agonism in 2014.

Each revision gave laboratories a new reason to study the molecule. This article follows that history in order. It then covers how laboratories use tianeptine reference materials today and where U.S. regulation stands as of October 2026.

Tianeptine Research Timeline At A Glance

1960s: Discovery At The French Society Of Medical Research

Tianeptine was discovered in the 1960s and patented by the French Society of Medical Research, according to the DEA's July 2026 Federal Register notice.

Its structure has a 3-ring dibenzothiazepine core and a 7-carbon aminoheptanoic acid side chain. The ring system resembles other tricyclic molecules. The side chain does not, and tianeptine's pharmacology turned out to differ from theirs as well.

Late 1980s: The Serotonin Uptake Hypothesis

The first widely cited explanation came from rat brain studies. They found that tianeptine lowered extracellular serotonin, and researchers attributed the drop to faster serotonin uptake. Tianeptine was then described as a serotonin uptake enhancer.

That explanation did not hold. A 2010 review in Molecular Psychiatry pointed out that tianeptine has low affinity for the serotonin transporter. Later microdialysis and electrophysiology studies also showed no consistent change in serotonin levels or in the firing of serotonergic neurons.

1990s To 2000s: Stress, Structural Plasticity, And Glutamate

Researchers then tested tianeptine in rodent stress models, and the results pointed to the glutamate system. The same review summarizes 5 findings:

• In hippocampal CA3, chronic stress shrinks dendrites. Tianeptine prevented the shrinkage and could reverse it while glucocorticoid exposure continued.
• In the basolateral amygdala, stress increases dendritic branching. Tianeptine prevented the increase.
• In the dentate gyrus, tianeptine countered the stress-related drop in cell proliferation.
• At CA3 synapses of stressed rats, tianeptine normalized the ratio of NMDA to AMPA/kainate receptor currents.
• Repeated tianeptine exposure increased phosphorylation of the AMPA receptor GluR1 subunit in the hippocampus and frontal cortex.

The 7 authors wrote that "Converging lines of evidences demonstrate actions of tianeptine on the glutamatergic system." They also noted that the link between neurogenesis and cognition was still debated.

Our guides to tianeptine's mechanism of action in laboratory research and tianeptine's role in glutamate receptor research cover these pathways in more depth.

2014: The Mu-Opioid Receptor Finding

In 2014, a receptor pharmacology study in Translational Psychiatry revised the explanation again. Its authors wrote: "Herein, we report the characterization of tianeptine as a μ-opioid receptor (MOR) agonist." The 2014 study reported 4 results:

• Binding at the human MOR with a Ki of 383 nM
• G protein activation at the human MOR with an EC50 of 194 nM
• Full agonism at the delta-opioid receptor at much lower potency, with an EC50 of 37.4 μM at the human receptor
• No activity at the kappa-opioid receptor

A 2017 study in Neuropsychopharmacology then tested the finding in animals. It reported that tianeptine's acute and chronic behavioral effects in mice require MOR.

For laboratories, this added opioid receptor pharmacology to the fields that work with tianeptine. It is also the pharmacology the DEA cites in its 2026 scheduling proposal.

How Laboratories Use Tianeptine Today

Product documentation and published studies describe 7 laboratory uses:

• Analytical reference standard for chromatography and mass spectrometry method development
• Calibration material for quality control procedures
• Forensic reference material for toxicology method validation
• Opioid receptor binding and G protein activation assays
• Glutamate signaling and synaptic plasticity studies in hippocampal preparations
• Neuroinflammation studies. A 2018 study in primary rat microglial cultures found that tianeptine reduced markers of M1 activation after lipopolysaccharide stimulation.
• Structure-activity comparisons with other tricyclic molecules

Salt Forms And Batch Documentation

Published studies describe the tianeptine molecule. Laboratories receive it as a salt. Nordic Chems stocks tianeptine sodium (CAS 30123-17-2, 458.9 g/mol) as a 10 g tianeptine sodium powder and as 12.5 mg tianeptine sodium capsules. We also stock tianeptine sulfate capsules. Per-unit masses are nominal reference masses for documentation and inventory control.

Once either salt dissolves, the same tianeptine ion is in solution. The salt choice changes moisture uptake, storage, and stock preparation. The pharmacology stays the same. Our tianeptine sodium vs. tianeptine sulfate comparison covers the chemistry of each form.

Every tianeptine batch is tested by 2 independent labs, BioRegen Labs in Houston and Janoshik Analytical in Prague, with HPLC and mass spectrometry. We reject any batch below 99% purity. Each certificate of analysis (COA) lists the batch number and test date. Match that number to the container before the material goes into a study, and follow the safety data sheet (SDS) for handling, storage, and disposal.

U.S. Regulatory Status As Of October 2026

Tianeptine is not approved by the FDA for any medical use.

On July 8, 2026, the DEA published a proposed rule to place tianeptine in Schedule I of the Controlled Substances Act (91 FR 42150). The comment period closed on August 7, 2026. As of October 13, 2026, the DEA had not published a final rule. If the rule is finalized, only DEA-registered researchers could handle tianeptine.

State law already restricts it. More than 20 states schedule tianeptine or ban its retail sale, and our 2026 update on states that have banned or restricted tianeptine lists each one. Nordic Chems blocks orders bound for those states. Confirm your state's schedule and your institution's rules before any tianeptine work begins.

Research Use Only

Nordic Chems sells tianeptine for laboratory research and analytical purposes only. It is not for human or animal consumption. We explain the policy in why tianeptine is strictly for research.

For questions about batch documentation or laboratory protocols, contact our team or read our frequently asked questions.

FAQs

When was tianeptine discovered?

Tianeptine was discovered in the 1960s and patented by the French Society of Medical Research, according to the DEA's July 2026 Federal Register notice. It has been a subject of published neuroscience research for more than 3 decades.

Why was tianeptine called a serotonin uptake enhancer?

Rat brain studies in the late 1980s found that tianeptine lowered extracellular serotonin, and researchers attributed that to faster uptake. A 2010 review in Molecular Psychiatry reported that tianeptine has low affinity for the serotonin transporter and that later studies showed no consistent serotonin change.

What did the 2014 mu-opioid receptor study find?

The 2014 study in Translational Psychiatry characterized tianeptine as a mu-opioid receptor agonist. It reported a Ki of 383 nM and an EC50 of 194 nM at the human receptor, weaker agonism at the delta-opioid receptor, and no activity at the kappa-opioid receptor.

What do laboratories use tianeptine for?

Laboratories use tianeptine as an analytical reference standard for chromatography and mass spectrometry, as a forensic reference material, and in receptor pharmacology assays. Published studies also use it in glutamate signaling, synaptic plasticity, and microglial culture work.

Does the salt form change tianeptine's pharmacology?

No. Tianeptine sodium and tianeptine sulfate release the same tianeptine ion once dissolved. The salt form changes moisture uptake, storage, and stock preparation. Tianeptine sodium is CAS 30123-17-2 at 458.9 g/mol.

Is tianeptine a controlled substance in the United States?

Tianeptine is not federally scheduled as of October 13, 2026. The DEA proposed placing it in Schedule I on July 8, 2026, and the comment period closed on August 7, 2026. More than 20 states already schedule it or ban its retail sale. It is not approved by the FDA for any medical use.

How can I verify the identity and purity of tianeptine on receipt?

Check that the batch number on the certificate of analysis matches the container, and that the certificate names the lab, the test date, and the methods. Nordic Chems batches are tested with HPLC and mass spectrometry. Email support@nordicchems.is with your order number and we will tell you which batch it came from.